首页 | 本学科首页   官方微博 | 高级检索  
检索        


Oxidised low‐density lipoprotein,a possible distinguishing lipid profile biomolecule between prostate cancer and benign prostatic hyperplasia
Authors:George Awuku Asare  Emmanunella Owusu‐Boateng  Bernice Asiedu  Brodrick Yeboah Amoah  Eric Essendoh  Rabin Yitzhak Otoo
Abstract:Benign prostatic hyperplasia (BPH) and prostate cancer (PCa) share common conditions such as lower urinary tract symptoms (LUTS) and dyslipidaemia. Whether an extensive lipid profile analysis could discriminate between BPH and PCa was the objective. Thirty‐six (36) BPH and twenty (20) PCa outpatients of a urology clinic plus forty (40) controls without LUTS, but normal PSA, were recruited. Body mass index (BMI), lipid profile (total cholesterol CHOL], triglycerides TG], high‐density lipoprotein HDL], very‐low‐density lipoprotein VLDL], low‐density lipoprotein LDL] and Castelli's risk index I CR I] TC/HDL]), oxidised LDL, apolipoprotein E, ceramide and PSA were determined. Mean ages for BPH, PCa and control were 69 ± 13, 67 ± 10 and 53 ± 7 years respectively. Most parameters apart from BMI and HDL were significantly different compared to the control group. oxLDL for BPH versus control, PCa versus control and BPH versus PCa was significant (p < 0.001, p = 0.02 and p < 0.001 respectively). Ceramide showed significant group differences. Between BPH and PCa, total cholesterol, LDL and Apo E were significantly different (p = 0.00, p = 0.01 and p = 0.03 respectively). Apo E could potentially be a discriminating biomarker. Receiver operating characteristic curves for TPSA, Apo E and oxLDL demonstrated sensitivity of 69.44 and specificity of 88.24 for oxLDL, hence more discriminatory.
Keywords:Apo E  benign prostatic hyperplasia  lipid profile  prostate cancer
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号